At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
JNJ-42165279 +1 moredrug
Likely dose
JNJ-42165279 25 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.
In Brief
A Phase 2 clinical trial evaluating JNJ-42165279 and Placebo for Phobic Disorders. Completed, enrolled 150 participants across 21 sites in 3 countries.
Detailed Summary
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhobic Disorders
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJun 2015
Primary CompletionAug 2018
TodayJul 2026
First PostedMay 4, 2015
Enrollment StartJun 11, 2015
Primary CompletionAug 9, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.2 years ago
Interventions
JNJ-42165279drug
Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
Placebodrug
Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.